JENTADUETO XR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).

How it works

JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.

What the body does with it

Metabolism	Linagliptin: minimal metabolism, primarily excreted unchanged in feces (80%) and urine (5%). Metformin: not metabolized, excreted unchanged in urine (90%) via tubular secretion.
Excretion	Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Half-life	Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Protein binding	Linagliptin: 70–80% bound to plasma proteins, saturable, concentration-dependent. Metformin: <5% bound to plasma proteins (negligible).
Volume of Distribution	Linagliptin: ~1110 L (large Vd, extensive tissue distribution). Metformin: 654–1372 L (mean ~654 L, indicating high tissue uptake).
Bioavailability	Linagliptin: ~30% oral bioavailability. Metformin: 40–60% oral bioavailability (extended-release); high interindividual variability.
Onset of Action	Oral: Linagliptin DPP-4 inhibition within 30 min post-dose; metformin reduces hepatic glucose production within 1–2 h. Peak effect after several days.
Duration of Action	Linagliptin: >24 h (once-daily dosing maintains >80% DPP-4 inhibition). Metformin: 12–24 h (extended-release formulation). Clinical glycemic effects persist over 24 h with regular dosing.

Classification & Brands

Dosing & administration

The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	eGFR ≥45 mL/min/1.73 m²: no dose adjustment needed. eGFR 30-44: discontinue JENTADUETO XR; use individual components or lower dose metformin if appropriate. eGFR <30: contraindicated.
Liver impairment	Avoid use in patients with hepatic impairment (Child-Pugh Class A, B, or C) due to risk of lactic acidosis from metformin component.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years; no specific dosing guidelines available.
Geriatric use	In patients aged ≥65 years, assess renal function before initiating therapy. Use with caution due to age-related decline in renal function and increased risk of volume depletion. Consider starting at lower dose of empagliflozin (5 mg) and titrate gradually.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).

Breastfeeding	Metformin is excreted in human milk; M/P ratio 0.35–0.65. Linagliptin likely excreted. Caution; weigh benefits vs risks. Avoid in breastfeeding if possible.
Teratogenic Risk	FDA Pregnancy Category B. Animal studies show no fetal harm. Limited human data; risk cannot be excluded. First trimester: no confirmed risk. Second/third trimester: theoretical risk of neonatal lactic acidosis with metformin; avoid.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Lactic Acidosis: Metformin-associated lactic acidosis (MALA) is a rare but serious adverse event; risk factors include renal impairment, hypoxia, sepsis, and acute congestive heart failure.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe renal impairment (eGFR < 30 mL/min/1.73 m²)","Acute or chronic metabolic acidosis including diabetic ketoacidosis","Hypersensitivity to linagliptin, metformin, or any component of the tablet"]

Clinical Precautions

Precautions

["Lactic acidosis risk (metformin component)","Pancreatitis (linagliptin)","Acute kidney injury or renal impairment (metformin)","Hypoglycemia risk when used with insulin or sulfonylureas","Hypersensitivity reactions (angioedema, anaphylaxis, urticaria)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

JENTADUETO XR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).

How it works

What the body does with it

Metabolism	Linagliptin: minimal metabolism, primarily excreted unchanged in feces (80%) and urine (5%). Metformin: not metabolized, excreted unchanged in urine (90%) via tubular secretion.
Excretion	Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Half-life	Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Protein binding	Linagliptin: 70–80% bound to plasma proteins, saturable, concentration-dependent. Metformin: <5% bound to plasma proteins (negligible).
Volume of Distribution	Linagliptin: ~1110 L (large Vd, extensive tissue distribution). Metformin: 654–1372 L (mean ~654 L, indicating high tissue uptake).
Bioavailability	Linagliptin: ~30% oral bioavailability. Metformin: 40–60% oral bioavailability (extended-release); high interindividual variability.
Onset of Action	Oral: Linagliptin DPP-4 inhibition within 30 min post-dose; metformin reduces hepatic glucose production within 1–2 h. Peak effect after several days.
Duration of Action	Linagliptin: >24 h (once-daily dosing maintains >80% DPP-4 inhibition). Metformin: 12–24 h (extended-release formulation). Clinical glycemic effects persist over 24 h with regular dosing.

Classification & Brands

Dosing & administration

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	eGFR ≥45 mL/min/1.73 m²: no dose adjustment needed. eGFR 30-44: discontinue JENTADUETO XR; use individual components or lower dose metformin if appropriate. eGFR <30: contraindicated.
Liver impairment	Avoid use in patients with hepatic impairment (Child-Pugh Class A, B, or C) due to risk of lactic acidosis from metformin component.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years; no specific dosing guidelines available.
Geriatric use	In patients aged ≥65 years, assess renal function before initiating therapy. Use with caution due to age-related decline in renal function and increased risk of volume depletion. Consider starting at lower dose of empagliflozin (5 mg) and titrate gradually.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JENTADUETO XR (JENTADUETO XR).

Breastfeeding	Metformin is excreted in human milk; M/P ratio 0.35–0.65. Linagliptin likely excreted. Caution; weigh benefits vs risks. Avoid in breastfeeding if possible.
Teratogenic Risk	FDA Pregnancy Category B. Animal studies show no fetal harm. Limited human data; risk cannot be excluded. First trimester: no confirmed risk. Second/third trimester: theoretical risk of neonatal lactic acidosis with metformin; avoid.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Lactic Acidosis: Metformin-associated lactic acidosis (MALA) is a rare but serious adverse event; risk factors include renal impairment, hypoxia, sepsis, and acute congestive heart failure.